Febrile Neutropenia Clinical Trial
Official title:
The Effect, Safety and Pharmacoeconomics of First or Second Level-prophylactic Use of PEG-rhG-CSF in Breast Cancer Patients With Medium-high Risk of Febrile Neutropenia During Chemotherapy
This clinical study is a multiple center, registering and real-world conditional research. The breast cancer patients planning for chemotherapy evaluated with medium-high risk of febrile neutropenia (FN) are recruited, receiving the first level prophylactic use of PEG-rhG-CSF or the second level prophylactic use of PEG-rhG-CSF in at least two cycles of chemotherapy according to real-world clinical judgement and choice by physicians in local cancer center. Comparing real conditional-FN rate, FN-caused hospitalization rate and antibiotic use rate, direct/indirect medical cost.
The breast cancer patients planning for neo-adjuvant/adjuvant chemotherapy evaluated with medium-high risk of febrile neutropenia (FN) according to NCCN and ASCO guideline are recruited, receiving the first level prophylactic use of PEG-rhG-CSF or the second level prophylactic use of PEG-rhG-CSF according to real-world clinical judgement and choice by physicians in local cancer center for at least two cycles of chemotherapy. The primary outcome is FN rate, the second outcomes are rate of 3-4 grade decrease of ANC, FN-caused hospitalization, FN-caused antibiotic use rate, rate of reduction of chemotherapy dose, delay of chemotherapy, safety and pharmacoeconomics. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03641131 -
Ampholipad Real-World Data in Taiwan
|
||
| Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A | |
| Completed |
NCT04914702 -
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
|
||
| Completed |
NCT02728596 -
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
|
N/A | |
| Completed |
NCT03104595 -
Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02536599 -
Risk Factors & Outcomes for Clinically Documented Infections in Pediatric Cancer Patients With Fever & Neutropenia
|
||
| Completed |
NCT02005783 -
Study of Danggui Buxue Decoction in Preventing Neutropenia
|
Phase 2 | |
| Recruiting |
NCT03449693 -
Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia
|
Phase 2 | |
| Recruiting |
NCT05149547 -
mNGS Versus Blood Culture in FN
|
||
| Recruiting |
NCT05584930 -
Clusterin, Ptx3 and Pediatric Febrile Neutropenia (CluPPFeN)
|
N/A | |
| Completed |
NCT04134429 -
Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
|
||
| Recruiting |
NCT01684189 -
Registry of Febrile Neutropenia and Invasive Fungal Infections
|
N/A | |
| Completed |
NCT00462878 -
Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation
|
N/A | |
| Completed |
NCT00035425 -
Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection
|
Phase 3 | |
| Recruiting |
NCT04948463 -
Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia
|
Phase 4 | |
| Recruiting |
NCT03740464 -
Long-acting G-CSF for Febrile Neutropenia
|
Phase 3 | |
| Not yet recruiting |
NCT06116734 -
Lapelga vs Gastrofil
|
Phase 3 | |
| Completed |
NCT00503854 -
Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
|
||
| Terminated |
NCT02732327 -
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
|
Phase 2 | |
| Completed |
NCT01114165 -
Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients
|
Phase 4 |